VGLUT1 | Reduced protein levels before cell loss and onset of pathology (56)– (58) |
VGLUT2 | Reduced protein levels before cell loss and onset of pathology (56)– (58) |
GLAST/EAAT1 | Reduced protein at early clinical stages (59), (60) |
GLT-1/EAAT2 | Reduced protein levels at early clinical stages (59), (60) |
Glutamine synthetase | Reduced protein levels (61) |
NMDA receptor | Increased protein levels in mild cognitive impairment (36) |
NR1 | Reduced protein levels (62) |
NR2A–B | Reduced protein levels (63) |
NR2C–D | Unaffected (63) |
NR3 | Not assessed |
AMPA receptor | Variable results indicate that there is initial increase at very early stages before a reduction in GluR1 and increased GluR2/3 at later stages (64)– (66) |
GLUR1–3 |
GLUR4 | Not assessed |
Kainate receptor | Reduced receptor binding (67) |
GLUR5–7 | Reduced expression (68) |
Metabotropic receptor |
mGluR 1 | Reduced protein levels (67), (69) |
mGluR 2 | Increased protein levels (70) |
mGluRs 3–7 | Not assessed |